Effect of initial anti-infective regimen covering Pseudomonas aeruginosa on clinical outcome for inpatients with bronchiectasis exacerbation
Objective To evaluate the clinical outcome of an anti-infective strategy initially covering Pseudomonas aeruginosa for inpatients with bronchiectasis exacerbation.Methods Inpatients with bronchiectasis exacerbation admitted to the Department of Respiratory and Critical Care Medicine of the Affiliated Hospital Xuzhou Medical University between January 2019 and June 2021 were retrospectively grouped according to whether the anti-infective strategy covered Pseudomonas aeruginosa.A total of 125 patients were assigned to Group 1,which received initial antibiotic therapy that failed to cover Pseudomonas aeruginosa.A total of 197 patients were assigned to Group 2,which received initial antibiotic therapy that covered Pseudomonas aeruginosa.Days of antibiotic usage during hospitalization,length of stay,dyspnea and quality of life,pulmonary function,inflammation indices,the time to next exacerbation after discharge,and the total number of annual outpatient visits and hospitalizations due to bronchiectasis exacerbation during the follow-up period were analyzed statistically.Results Dyspnea and quality of life,pulmonary function and inflammation indices of inpatients with bronchiectasis exacerbation were considerably ameliorated before and after treatment in both groups.Compared to Group 1,initial antibiotic therapy covering Pseudomonas aeruginosa,was associated with extending the time to the next exacerbation after discharge and reducing the frequencies of hospitalization and outpatient visits.Conclusion Anti-infective strategy initially covering Pseudomonas aeruginosa during hospitalization not only has a good therapeutic effect but can also significantly lessen the frequencies of bronchiectasis exacerbation and extend the time to the next exacerbation.
NETL
NSTL
万方数据
维普
